Associated Genetic Biomarkers
BRD3 is altered in 2.23% of all cancers with colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, melanoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations .
The most common alterations in BRD3 are BRD3 A273T (0.11%), BRD3 T189P (1.63%), BRD3 P194S (0.06%), BRD3 R441H (0.07%), and BRD3 E496_K500del (0.04%) .
BRD3 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains BRD3 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with BRD3 status in the inclusion eligibility criteria most commonly target lymphoma and malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is BRD3 Fusion .
Bms-986158 is the most frequent therapy in trials with BRD3 as an inclusion criteria .
Significance of BRD3 in Diseases
Malignant Solid Tumor +
Central Nervous System Lymphoma +
BRD3 is an inclusion criterion in 1 clinical trial for central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRD3 status and central nervous system lymphoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.